Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.616
Neutral
RSI(14)
49.643
Neutral
STOCH(KDJ)(9,3,3)
38.331
Neutral
ATR(14)
1.127
High Vlolatility
CCI(14)
-73.202
Neutral
Williams %R
62.304
Sell
TRIX(12,20)
0.148
Sell
StochRSI(14)
54.881
Buy
Search
Roivant Sciences Ltd
ROIVAdd to Watchlist
33.920USD
-0.600-1.74%
Close 07-31 16:00（ET）Quotes delayed by 15 min
24.43BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.74%
5 Days
-3.11%
1 Month
-4.15%
6 Months
+56.89%
Year to Date
+56.31%
1 Year
+198.59%
Key Figures
34.410Open
34.500High
5.40MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.75%Turnover Ratio
34.520Prev. Close
33.540Low
133.22MTurnover
LossP/E Static
5.40P/B
0.00%Div Yield TTM
-7.14%ROA
32.79252wk High
1.22Volume Ratio
-171.98MNet Profit
720.35MShares
-0.4320EPS TTM
1.14Beta
-6.51%ROE
10.59452wk Low
2.78%Amplitude
87.30%Gross Margin
24.43BMarket Cap
-0.85Reward/Risk
2.03%Risk Rate
TradingKey Stock Score of Roivant Sciences Ltd
Currency: USD Updated: 2026-07-31Key Insights
Roivant Sciences Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 37.53.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Roivant Sciences Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Roivant Sciences Ltd Highlights
StrengthsRisks
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.26M.
Undervalued
The company’s latest PE is -78.49, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 565.52M shares, decreasing 3.91% quarter-over-quarter.
Held by David Einhorn
Star Investor David Einhorn holds 2.02M shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
37.528
Target Price
+14.17%
Upside Space
Roivant Sciences Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
12
analysts
Buy
Current Rating
37.528
Target Price
+14.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Roivant Sciences Ltd
ROIV
12
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
33.972
Sell
MA10
34.389
Sell
MA20
34.861
Sell
MA50
32.567
Buy
MA100
30.454
Buy
MA200
26.423
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Roivant Sciences Ltd Info
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Ticker SymbolROIV
CompanyRoivant Sciences Ltd
CEOVenker (Eric)
Websitehttp://roivant.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Roivant Sciences Ltd (ROIV)?
The current price of Roivant Sciences Ltd (ROIV) is 33.92.
What is the symbol of Roivant Sciences Ltd?
The ticker symbol of Roivant Sciences Ltd is ROIV.
What is the 52-week high of Roivant Sciences Ltd?
The 52-week high of Roivant Sciences Ltd is 32.79.
What is the 52-week low of Roivant Sciences Ltd?
The 52-week low of Roivant Sciences Ltd is 10.59.
What is the market capitalization of Roivant Sciences Ltd?
The market capitalization of Roivant Sciences Ltd is 24.43B.
Is Roivant Sciences Ltd (ROIV) currently rated as Buy, Hold, or Sell?
According to analysts, Roivant Sciences Ltd (ROIV) has an overall rating of Buy, with a price target of 37.53.
What is the Earnings Per Share (EPS TTM) of Roivant Sciences Ltd (ROIV)?
The Earnings Per Share (EPS TTM) of Roivant Sciences Ltd (ROIV) is -0.43.